Anguidine: a broad phase II study of the Southeastern Cancer Study Group.

Anguidine, a phase II agent, was used to treat 276 patients with solid tumors. The overall evaluability rate was 68%. Hematologic toxicity was substantial but not prohibitive. There were no complete responses, two partial responses, and 12 stabilizations.